In a collaboration that will bring together service providers and CROs, newly launched KPI Therapeutics is aiming to speed the development of new drug candidates for Seattle-based biotech Kineta.
The Institute of Cancer Research, London, became the latest member of a consortium seeking to integrate magnetic resonance imaging into radiation therapy.
Senseonics has raised a $20 million venture round to get its implantable blood glucose monitor for diabetics through pivotal trials.
Boehringer Ingelheim persuaded EU officials to put its lung-disease drug nintedanib on its development fast track, speeding its path to market as a treatment for idiopathic pulmonary fibrosis.
AbbVie is awaiting the decisions of regulators for its closely followed new interferon-free, oral hepatitis C drug that will go head-to-head with Sovaldi. And it has lined up its production horses so that it will be ready to blast out of the gates if approvals are granted in the U.S. and Europe.
Syndax Pharmaceuticals is looking to raise $69 million in an IPO, planning to move 4.3 million shares at between $13 and $15 apiece.
After a costly string of defeats with the heart drug darapladib, GlaxoSmithKline's cardio unit is rolling into Phase III with another cardiac hopeful, launching an expansive late-stage effort for losmapimod, designed to prevent repeat heart attacks.
Like we always do about this time of year, FierceBiotech is kicking off its search for the next class of Fierce 15 companies, and we want to hear from you. It's easy: Just fill out the form embedded below or find it here.
Halozyme is back on track with a midstage trial of its in-development pancreatic cancer treatment after the FDA lifted its clinical hold on enrollment, news that sent the company's shares up as much as 20%.
PharmAthene's anthrax vaccine candidate, SparVax, works at least as well as currently licensed BioThrax from Emergent BioSolutions--at least, according to a study in New Zealand white rabbits.